MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Nevro taps ex-Thoratec CEO Grossman | Personnel Moves, March 20, 2019

Nevro taps ex-Thoratec CEO Grossman | Personnel Moves, March 20, 2019

By

Nevro taps ex-Thoratec CEO GrossmanNevro Corp. (NYSE:NVRO) said yesterday that it named former Thoratec CEO Keith Grossman to replace president & CEO Rami Elghandour after striking a deal with one of its investors, Broadfin Capital.

Grossman re-joined Thoratec after taking over at Conceptus in December 2011 and leading it to a $1.1 billion sale to Bayer in June 2013 (he’d been Thoratec’s CEO from 1996-2006). Grossman helmed Thoratec until St. Jude Medical (now Abbott) acquired it in October 2015 for $3.3 billion.

Nevro said the deal with Broadfin also involves the expansion of its board of directors with the addition of Warburg Pincus limited partner Bess Weatherman and medtech veteran Kevin O’Boyle and the departure of director Ali Behbahani. Broadfin picked up a 5.8% stake in Nevro in September 2015 but cut that to less than 0.2% in February 2017, according to regulatory filings.

“On behalf of the board and our entire company, I am excited to welcome Keith Grossman to the Nevro team,” chairman Michael DeMane said in prepared remarks. “Keith brings over 30 years of experience in leading innovative medical technology companies through periods of strategic change to deliver growth and enhanced value for stockholders. As we look to the future, I am confident that under Keith’s direction, Nevro will be well positioned to capture a burgeoning market opportunity with its pioneering spinal cord stimulation (SCS) technology to treat chronic pain.”

“I am excited by this opportunity to join such a talented team at a pivotal moment in Nevro’s history,” Grossman added. “Over the past several years, Nevro has leveraged the strength of its technology to enhance patient care and drive overall industry growth. Nevro is now at an inflection point, and I am confident in our ability to continue delivering value not only to our patients and customers, but importantly, to our stockholders. I look forward to working closely with the board and the full Nevro team to advance the company into its next phase of growth.”

Broadfin also agreed to back Nevro’s board nominees at its next shareholders meeting and to obey standstill provisions and voting commitments. Nevro said it’s suspending its revenue guidance pending Grossman’s assessment.

NVRO shares were up 25.0% to $55.96 apiece today in pre-market trading ahead of a $44.51-per-share open and jumped 33.8% to $59.91 shortly thereafter.

 Synaptive Medical names Clarke as CFO
Synaptive Medical said it named Sandra Clarke as its new finance chief.

“Ms. Clarke is an incredible addition to our team,” CEO Peter Wehrly said in prepared remarks. “With her accomplished background and experience working for companies at critical inflection points, Ms. Clarke will play a key role at Synaptive as we continue expanding our presence globally.”

“I’m very excited to join Synaptive and work closely with the team to continue advancing their efforts in transforming neurosurgical technologies,” Clarke added. “Given the increasing need for advanced neurological care, I’m pleased to be working for a company that is committed to providing physicians the tools necessary to achieve optimal patient outcomes.”
Read More

 ElectroCore CFO Vraniak taps out, Posner taps in
ElectroCore CFO Glenn Vraniak is resigning effective April 1 and is to be replaced by Cellectar Biosciences finance chief Brian Posner.
Read More

 Rosenzweig joins Check-Cap as CFO
Check-Cap (NSDQ:CHEK) said it appointed former Entera Bio (NSDQ:ENTX) CFO Mira Rosenzweig as its own finance chief, effective April 28.
Read More

 Ex-K2M CIO Staubach lands at Tactile Medical
The new chief information officer at Tactile Systems Technology (NSDQ:TCMD) is ex-K2M CIO Peter Schaubach.
Read More

In case you missed it

RSS From Medical Design & Outsourcing

  • 5 of the latest cardiac tech insights out of ACC.21
    The American College of Cardiology’s 70th Annual Scientific Session has produced some positive news about some controversial cardiac tech. Drug-coated stents, which a 2018 study linked to late-stage death, were shown to be non-inferior to non-drug-coated stents in patients with peripheral arterial disease. And a new study of renal denervation that used a different methodology… […]
  • Viant expands ortho plant in France
    Viant announced today that it completed a more than $8 million expansion of its France-based Orthopedic Implant & Coating Center of Excellence. Foxborough, Mass.-based Viant’s Chaumont, France facility expansion includes a new building with a controlled-environment room and an investment in recently FDA-cleared vacuum plasma spray (VPS) coating technology, according to a news release. The… […]
  • How will clinical trials be conducted in the future?
    The COVID-19 lockdown compelled clinical trial managers and regulatory compliance officers to innovate in ensuring that critical testing moved forward while the world had shut down. With life shifting back, how much of these new measures will remain in place? Join us on Tuesday, May 18 on DeviceTalks Tuesdays to hear representatives from Medtronic, Hologic… […]
  • Edwards Lifesciences tricuspid valve reduced leakage in 98% of patients
    Edwards Lifesciences‘s Evoque tricuspid valve replacement system reduces tricuspid heart valve leakage to non-traceable or mild leakage in 98% of patients, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session. Evoque is designed to replace native tricuspid valves without open-heart surgery. The valve is implanted using a minimally… […]
  • DTW Podcast: Getting to the heart of Boston Scientific’s peripheral business; How Hologic sees trials changing
    In this week’s episode of the DeviceTalks Weekly Podcast, Boston Scientific peripheral business EVP Jeff Mirviss explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and other critical “highways” in the body. Mirviss explains where the peripheral business is headed, and why Boston Scientific is uniquely positioned to address the business.… […]
  • ReCor Medical has positive renal denervation study news
    ReCor Medical‘s renal denervation significantly reduced blood pressure among people with drug-resistant hypertension, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session. The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry,… […]
  • CMS delays Medicare payments for breakthrough devices until December
    Medicare coverage for FDA-designated breakthrough medical devices will have to wait several more months, despite broad support. The Centers for Medicare and Medicaid Services (CMS) issued a final rule on Medicare Coverage of Innovative Technology (MCIT) in January, granting coverage for breakthrough devices the same day as their FDA approvals, for up to four years. Immediately… […]
  • This imaging device could be a breakthrough for breast cancer treatment
    OncoRes Medical’s system may detect cancer cells on a microscopic scale during a lumpectomy, potentially averting the need for a second breast cancer surgery. Having breast surgery to remove a cancerous lump is traumatic enough. Learning that you’ll need another operation to remove cancer cells that the surgeon couldn’t detect the first time only adds… […]
  • Americans apparently trust healthcare professionals more than FDA, CDC
    As the U.S. tries to reach a post-COVID-19 pandemic “normal,” Americans are placing more trust in nurses and doctors than agencies such as the CDC and FDA, according to a new survey from the Robert Wood Johnson Foundation and Harvard T.H. Chan School of Public Health. The survey — conducted Feb. 11 – March 15,… […]
  • May 2021 Issue: Unmasking the response to the next pandemic
    3M, others may have unmasked a solution to future N95 shortages The 10 largest orthopedic device companies in the world How big medtech fared during a year of COVID-19 Medtech moves beyond the pandemic The COVID-19 pandemic is still very much with us, and medtech companies continue churning out devices to meet coronavirus patient needs.… […]
  • FDA warns about consumer electronics and implanted devices
    The FDA is advising the public that certain consumer devices have high-field strength-magnets that can send medical devices into “magnet mode.” Magnets of this nature can affect the normal operations of implanted medical devices until the magnetic field is moved, according to the FDA news release. These medical devices are designed with a “magnet mode”… […]